| scholarly article | Q13442814 |
| P50 | author | Meritxell Canals | Q46120848 |
| J. Robert Lane | Q63923479 | ||
| P2093 | author name string | Alaa Abdul-Ridha | |
| P2860 | cites work | Crystal structure of the β2 adrenergic receptor-Gs protein complex | Q24635327 |
| beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice | Q24654027 | ||
| ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL | Q27861036 | ||
| GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells | Q28506327 | ||
| Differential signal transduction by five splice variants of the PACAP receptor | Q28566746 | ||
| Beta-arrestins and cell signaling | Q29616793 | ||
| Insights into G protein structure, function, and regulation. | Q30336381 | ||
| Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling | Q30432989 | ||
| Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors | Q30468685 | ||
| Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation | Q30489795 | ||
| Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties | Q30498538 | ||
| Identification of allosteric peptide agonists of CXCR4. | Q30868390 | ||
| Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands | Q30936859 | ||
| A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. | Q33779634 | ||
| Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery | Q33890786 | ||
| Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3 | Q34007358 | ||
| Regulation of GABA(A) receptor subunit expression by pharmacological agents. | Q34096251 | ||
| Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 | ||
| Allosteric binding sites on cell-surface receptors: novel targets for drug discovery | Q34139176 | ||
| Trends in the exploitation of novel drug targets | Q34205159 | ||
| M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. | Q34397201 | ||
| Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. | Q34536660 | ||
| mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082. | Q34558000 | ||
| Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. | Q34719701 | ||
| Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist | Q34881143 | ||
| Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists | Q35001258 | ||
| Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. | Q35213193 | ||
| Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. | Q35264421 | ||
| A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation | Q35643821 | ||
| Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. | Q35688511 | ||
| beta-arrestins: traffic cops of cell signaling | Q35804809 | ||
| Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation | Q35874442 | ||
| A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling | Q36082162 | ||
| Benzodiazepine treatment induces subtype-specific changes in GABA(A) receptor trafficking and decreases synaptic inhibition | Q36389492 | ||
| Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells | Q36638807 | ||
| Therapeutic potential of β-arrestin- and G protein-biased agonists. | Q36773331 | ||
| Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. | Q36870038 | ||
| Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. | Q36880915 | ||
| GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition | Q37125949 | ||
| Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling | Q37209196 | ||
| Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands | Q37210835 | ||
| Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders | Q37360436 | ||
| Endosomes: a legitimate platform for the signaling train | Q37394435 | ||
| Allostery in GPCRs: 'MWC' revisited. | Q37932797 | ||
| Regulation of neuronal GABA(B) receptor functions by subunit composition | Q38010955 | ||
| Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors | Q38014954 | ||
| GABAergic modulation of benzodiazepine binding site sensitivity | Q39201870 | ||
| Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor | Q39699358 | ||
| Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation | Q39797234 | ||
| The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? | Q39907784 | ||
| Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis | Q40173956 | ||
| Src-mediated tyrosine phosphorylation of dynamin is required for beta2-adrenergic receptor internalization and mitogen-activated protein kinase signaling | Q40982696 | ||
| The benzodiazepine binding site of GABAA receptors | Q41679474 | ||
| Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. | Q41883529 | ||
| Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation | Q42428997 | ||
| Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. | Q42528174 | ||
| Cellular morphine tolerance produced by βarrestin-2-dependent impairment of μ-opioid receptor resensitization. | Q44350690 | ||
| Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators | Q45034314 | ||
| Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study | Q45249900 | ||
| Allosteric modulators affect the internalization of human adenosine A1 receptors | Q46743327 | ||
| Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration | Q48329195 | ||
| Allosteric Modulation of G Protein–Coupled Receptors | Q56115675 | ||
| Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands | Q57838214 | ||
| beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation | Q77452079 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | G protein-coupled receptor | Q38173 |
| P304 | page(s) | 527-534 | |
| P577 | publication date | 2013-02-21 | |
| P1433 | published in | ACS Chemical Neuroscience | Q2819059 |
| P1476 | title | Regulation of G protein-coupled receptors by allosteric ligands | |
| P478 | volume | 4 |
| Q34243209 | 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites |
| Q34076059 | Allosteric modulation of M1 muscarinic acetylcholine receptor internalization and subcellular trafficking |
| Q35967903 | Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors |
| Q38542934 | Current status of A1 adenosine receptor allosteric enhancers |
| Q90619385 | Development and Testing of Druglike Screening Libraries |
| Q47887304 | Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2. |
| Q27006721 | Drugs for allosteric sites on receptors |
| Q60717156 | Exploring the Active Conformation of Cyclohexane Carboxylate Positive Allosteric Modulators of the Type 4 Metabotropic Glutamate Receptor |
| Q47119819 | Functional expression of CCL8 and its interaction with chemokine receptor CCR3. |
| Q38211688 | Harnessing allostery: a novel approach to drug discovery |
| Q90501515 | Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach |
| Q36385771 | Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5. |
| Q35666067 | Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists |
| Q27696135 | Ligand-induced compaction of the PEX5 receptor-binding cavity impacts protein import efficiency into peroxisomes |
| Q36234465 | Peptide-guided targeting of GPR55 for anti-cancer therapy. |
| Q28545197 | Properties of protein drug target classes |
| Q34991036 | Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay |
| Q101121234 | Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors |
| Q30408394 | The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers |
| Q92409897 | Utilization of Biased G Protein-Coupled ReceptorSignaling towards Development of Safer andPersonalized Therapeutics |
Search more.